Jack Meehan of Operon Research sits down with Ajit Singh, CEO of Harbinger Health, to unpack the state of liquid biopsy and multi-cancer early detection. They discuss why Harbinger is targeting the “concerned” population rather than asymptomatic screening, and why the goal should be to “resolve” patients into a disposition rather than binarize them into a hard positive or negative. The conversation runs through the role of AI in diagnostics, Ajit’s view on dynamics around data and decentralization, market opportunities beyond the US, and the platform and cost economics that will decide who wins. It closes with Ajit’s outlook on consolidation, pharma’s growing role, and where investors have set their expectations wrong.
The video content available from this link is the property of Operon Research and is being providing strictly for the viewing by the recipient. Neither the link or the video may be shared with any parties nor can the contents of it replicated or shared.